Show Me The Data: Why Payers Need to See RWE Used in New Indication Approvals

Is Real-World Evidence to be trusted? Well-documented data can make a difference to both FDA and formulary decision makers, as described by Precision for Value’s Jeremy Schafer, Senior Vice President, Access Experience and Dan Danielson, Senior Director, Access Experience, writing in Managed Healthcare Executive.

To read the full article please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.